Spring 5-11-2012

An Investigation on the Interaction of Various Natural Products with the Amyloid-β Peptide; Betulinic Acid Causes Rapid Amyloid-β Fibril Formation at the Expense of Soluble Oligomers

Matthew Planchard
The University of Southern Mississippi

Follow this and additional works at: http://aquila.usm.edu/honors_theses

Part of the Medicine and Health Sciences Commons

Recommended Citation

This Honors College Thesis is brought to you for free and open access by the Honors College at The Aquila Digital Community. It has been accepted for inclusion in Honors Theses by an authorized administrator of The Aquila Digital Community. For more information, please contact Joshua.Cromwell@usm.edu.
AN INVESTIGATION ON THE INTERACTION OF VARIOUS NATURAL PRODUCTS WITH THE AMYLOID-β PEPTIDE; BETULINIC ACID CAUSES RAPID AMYLOID-β FIBRIL FORMATION AT THE EXPENSE OF SOLUBLE OLIGOMERS

by

Matthew Planchard

A Thesis

Submitted to the Honors College of The University of Southern Mississippi in Partial Fulfillment of the Requirements for the Degree of Bachelor of Science in the Departments of Biology and Chemistry-Biochemistry

March 2012
Approved by

Vijay Rangachari
Asst. Professor of Biophysical Chemistry

Sabine Heinhorst, Chair
Department of Chemistry-Biochemistry

Glen Shearer, Chair
Department of Biology

David R. Davies, Dean
Honors College
ABSTRACT

In this report we investigate the interaction of the natural compounds asiatic acid (AA), asiaticoside (AS), umbelliferone (UM), and betulinic acid (BA) with the amyloid-β (Aβ) peptide, the aggregation of which is implicated to be the major pathogenic event in Alzheimer's Disease (AD). Screening of compounds for ability to affect Aβ aggregation was performed via ThT fluorescence. Only BA showed consistent deviation from controls, causing virtually instantaneous formation of large amounts of fibrils in a concentration-dependent fashion. Turbidity assays ensured the aggregation monitored via ThT was not experimental aberration. Kinetics utilizing ThT and turbidity indicated that BA causes immediate exponential aggregation before leveling out within 15 min. SEC demonstrated the decrease in monomer caused by BA within 24 h and indicated that BA led to a decrease in oligomeric species. Sedimentation assays confirmed that large amounts of fibrils were formed in 24 h. Circular dichroism (CD) showed that BA caused instantaneous conversion of Aβ monomer from random coil to β-sheet, and that the maximal difference in secondary structure from controls was seen at 24 h. Immunoblots confirmed 24 h fibril formation, and also indicated that BA prevented the formation of oligomeric species found in control samples. Fluorescence anisotropy confirmed that BA binds to Aβ with a $K_D^{app}$ of $11.02 \pm 2.01 \mu M$. We conclude that AA, AS, and UM do not directly affect Aβ aggregation, while BA promotes rapid Aβ fibrilization at the expense of soluble oligomeric species. Because oligomers are the most neurotoxic form of Aβ, this suggests that BA should be further investigated as a potential therapeutic for AD.
CONTENTS

Introduction
Alzheimer's disease and amyloid-β ......................................................... 1
Aβ aggregation and oligomer toxicity ....................................................... 2
Aβ aggregation occurs via multiple pathways ......................................... 3
AD drug development ................................................................................ 3
Asiatic acid and asiaticoside ...................................................................... 5
Umbelliferone ............................................................................................ 7
Betulinic acid ............................................................................................ 8

Materials and Methods
Materials ...................................................................................................... 9
Preparation of Aβ42 monomers .................................................................. 9
Aβ42 oligomer generation ........................................................................ 10
Aβ aggregation reactions .......................................................................... 10
Fluorescence spectroscopy ..................................................................... 10
Turbidity .................................................................................................... 11
Kinetics ....................................................................................................... 11
Size exclusion chromatography (SEC) ...................................................... 12
Polyacrylamide gel electrophoresis (PAGE) and immunoblotting .......... 12
Circular dichroism (CD) .......................................................................... 13
Fluorescence anisotropy .......................................................................... 13

Results
AA, AS, and UM fail to inhibit Aβ42 fibrilization .................................... 14
BA rapidly augments Aβ42 fibril formation in a concentration
dependent manner .................................................................................. 16
Sedimentation and SEC assays also indicate rapid Aβ42
fibrilization in the presence of BA ......................................................... 20
Oligomers are absent in co-incubations of Aβ42 and BA ....................... 22
BA induces rapid changes in Aβ42 secondary structure ....................... 23
BA binds to monomeric Aβ42 with sub-micromolar binding affinity ....... 25

Discussion ................................................................................................. 26

References ............................................................................................... 30
**Introduction**

*Alzheimer's disease and amyloid-β*

Alzheimer's disease (AD) is a progressive, neurodegenerative disorder, and is the most common among all neurodegenerative diseases. It is characterized by such symptoms as acute memory loss and cognitive decline. These symptoms are caused by the deposition of amyloid-β (Aβ) peptide in the brain, forming what are known as senile plaques, and causing neuronal death, synaptic dysfunction, and loss of brain mass. These proteinaceous aggregates of Aβ are thought to be the main pathogenic species responsible for the neuronal loss and toxicity in AD brains. The generation of this hypothesis was driven largely by the recognition that the gene encoding Aβ is localized on chromosome 21 and that individuals with Down Syndrome – Trisomy 21 – invariably develop AD pathology. The hypothesis was further strengthened when several familial forms of AD were traced to mutations in the gene encoding amyloid precursor protein (APP). APP is a membrane-bound protein that is sequentially cleaved by two membrane-bound proteases (β- and γ-secretase, respectively) extracellularly to generate Aβ. This process is not inherently pathogenic, but changes in the cleavage cascade as a result of aging or mutations lead to the aggregation of Aβ. In particular, mutations in the presenilin genes (PS1 and PS2) have been shown to increase Aβ aggregation by altering the γ-secretase mediated cleavage to produce a residue of 42 amino acids (Aβ42), rather than the usual 40 (Aβ40). Aβ42 has a higher tendency for self aggregation and is the more neurotoxic of the two forms of Aβ.
**Aβ aggregation and oligomer toxicity**

The process of Aβ aggregation begins when monomeric Aβ spontaneously converts from random coil to β sheet secondary structure. This conversion allows multiple monomers to come together to form cross β sheet structures. Individual molecules of Aβ display a β strand, turn, β strand motif, and adjacent molecules of Aβ associate via intermolecular interaction of the R groups between the N-terminal β strand of one molecule and the C-terminal β strand of the other. In a process analogous to crystal growth, these small, oligomeric clumps of Aβ serve as nuclei for the recruitment of other Aβ monomers. This leads to a logarithmic growth phase, in which monomeric and oligomeric species go on to form insoluble fibrils, which in turn deposit in the brain as senile plaques. Much early research focused on the insoluble fibers and senile plaques as the pathogenic species of AD. However, more recent investigations suggest that the soluble, intermediate oligomers are the primary neurotoxic agents responsible for the symptoms of AD. These oligomers exist in equilibrium with the large plaque deposits, which serve as reservoirs of inactive protein. Microinjection of isolated oligomers in mice caused inhibition of long term potentiation (LTP), which is thought to be the molecular mechanism of memory formation, showing that oligomers exhibited toxicity even in the absence of monomers and insoluble fibrils. Indeed, the level of cognitive decline and the severity of AD symptoms correlates poorly with the level of insoluble plaque found in the brain. In addition, neuroinflammation has been shown to play a key role in the pathology of AD. This inflammation, mediated largely by microglial cells – the immune cells of the brain – has been shown to be triggered by the presence of oligomeric Aβ species, lending further credence to the hypothesis that oligomers are the primary causative agents of AD.
**Aβ aggregation occurs via multiple pathways**

Although the obligatory “on-pathway” in which monomers proceed continuously toward fibril formation is certainly a component of the AD disease cascade, recent research has indicated that Aβ monomer can follow multiple pathways of aggregation, some of which result in kinetically stable oligomers that fail to proceed to insoluble fibrils. Hypothesizing that endogenous interfaces, such as those formed by lipid rafts, influenced the Aβ aggregation pathway, Rangachari and colleagues showed that Aβ incubated in the presence of sodium dodecyl sulfate (SDS) micelles formed stable dimers and trimers, while removal of SDS caused these species to shift to unstable, higher molecular weight oligomers\(^{15}\). Another study found that the presence of non-esterified fatty acids (NEFAs) near to and above their critical micelle concentration (CMC) caused the formation of 12-18mers and 4-5mers, respectively, which remained kinetically trapped in an “off-pathway” as oligomers as long as NEFAs remained in the solution\(^{16}\). Removal of fatty acids allowed the oligomeric species to go on to form fibrils. However, even in the presence of NEFAs, an equilibrium exists between monomers, oligomers, and fibrils, suggesting that the on-pathway and off-pathway may occur simultaneously. It is possible that shifting this equilibrium *in vivo* could cause a decrease in the amount of highly toxic oligomeric species in favor of monomers or fibrillar aggregates.

**AD drug development**

Development or discovery of molecules that inhibit the aggregation of Aβ has been a major pursuit of AD research. A number of small molecule inhibitors, including some natural products, are reported to disrupt Aβ aggregation *in vitro* and reduce toxicity. Perhaps the most well known of these molecules is curcumin, a component of
turmeric\textsuperscript{17,18}. These molecules are thought to destabilize the Aβ fibrils and/or to significantly reduce the rate of aggregation, but the precise mechanism of inhibition is not yet clearly understood. Developing Aβ aggregation inhibitors poses several challenges: \textit{a}) it is extremely difficult to control the stage of inhibition during the aggregation process, and \textit{b}) inhibition of fibril formation may result in an increase in the concentrations of the intermediate oligomers along the aggregation pathway, which may prove to be more detrimental, as smaller soluble oligomers are known to more toxic than fibrils. Therefore, an ideal way of developing therapeutically viable aggregation inhibitors would be to trap Aβ at the monomeric level, since monomers are not toxic. However, it is difficult to design molecules against intrinsically disordered, monomeric Aβ due to its high conformational flexibility and lack of structurally well-defined recognition motifs.

Here, we report the interaction of various natural products with Aβ42 peptide and their effect on the latter’s aggregation process. Many natural products derived from plants have unique pharmacological properties that can be beneficial in the drug development process. Ancient forms of therapy, such as the ‘Ayurvedic’ type practiced in India, have extensively used plant products in the form of herbal concoctions for the treatment of numerous disorders, including those of the CNS. In this work, we report on the interactions of the natural compounds asiatic acid (AA), asiaticoside (AS), umbelliferone (UM), and betulinic acid (BA).
Asiatic acid and asiaticoside

*C. asiatica* has been traditionally used in Ayurvedic medicine to treat cognitive impairment and decline in a concoction comprising *C. asiatica* and three other herbs to be taken with milk\(^9\). The remedy is said to improve memory, prevent dementia, and fend off the negative effects of aging. It may also have anti-inflammatory effects.

In fact, *C. asiatica* has been investigated in several studies related to cognitive impairment or decline. Haleagrahara and Ponnusamy investigated the neuroprotective effect of an extract of *C. asiatica* on reactive oxygen species in rats that had been induced to have Parkinson's disease\(^{20}\). As in AD, the pathology of Parkinson's disease involves the creation of free radicals and the oxidative damage done by these radicals on the nerve tissues. In rats who were exposed to a compound chosen to induce oxidative damage and *C. asiatica* extract, levels of lipid hydroperoxides and protein-carbonyl content decreased while levels of total antioxidants and antioxidant enzyme levels increased, suggesting *C. asiatica* extract is capable of protecting the brain from free-radical induced damage. A study by Tiwari et al. investigated the effect of oral administration of *C. asiatica* extract on elderly patients in a hospital to determine its effect on mild cognitive impairment (MCI)\(^{21}\). After treatment, the participants exhibited an increase in mini mental status examination (MMSE) scores, a decrease in mean diastolic blood pressure, an increase in appetite, an improvement in their sense of well being, a decrease in insomnia, and a decrease in sensations of numbness and burning, perhaps due to anti-inflammatory effects of *C. asiatica* extract.
Patil et al. investigated the effect of asiatic acid, a component of the *C. asiatica* extract, along with withanolide A, another plant extract, on multiple targets associated with APP processing and the clearance of Aβ22. It was found that asiatic acid both upregulated the activity of the ADAM10 enzyme, which is involved in non-amyloidogenic processing of APP, and downregulated the activity of BACE1, a rate-limiting enzyme involved in the production of Aβ from APP. Asiatic acid was also investigated by Mook-Jung et al. for its protective effects against Aβ neurotoxicity23. The researchers used lab-grown cells and applied asiatic acid and two other asiaticoside derivatives to separate cell cultures. All three compounds were found to reduce cell death induced by hydrogen peroxide and to lower concentrations of free radicals within the
cells, with asiatic acid having the strongest effect. In addition, neither asiatic acid nor the other two compounds showed any toxicity or reduction in function of hippocampal cells. Another related study investigated the effect of eight semi-synthetic asiatic acid derivatives for their neuroprotective effect. This study found asiatic acid to be the most effective protector against neurotoxicity, demonstrating 97% protection against direct Aβ toxicity when Aβ was added to a culture of cells. In addition, a study by Boopathy et al. investigated asiatic acid's effect as an acetylcholinesterase inhibitor. Elevated acetylcholinesterase activity is a characteristic feature of AD. Asiatic acid was applied to hippocampal cell lines, and the cells were then assayed for acetylcholinesterase activity and for any potentially toxic effect of asiatic acid. Asiatic acid was found to be a very effective inhibitor of acetylcholinesterase while exhibiting no toxic effects on the hippocampal cells.

While all of these lines of research directly relate to AD and Aβ toxicity, we were unable to locate any studies directly investigating the effect of asiatic acid upon Aβ aggregation. Because of its clear potential to reduce Aβ toxicity, we have decided to investigate it herein, along with asiaticoside, a closely related compound also found in extracts of C. asiatica. We observed, however, that in spite of the established neuroprotective effect of C. asiatica extract and its derivatives, neither asiatic acid nor asiaticoside exhibited significant fibril inhibition in vitro.

**Umbelliferone**

Coumarin is a chemical family within the benzopyrene class. Among the coumarins is the natural product umbelliferone, which is a component of various Ayurvedic remedies for cognitive impairment. It is hydrophobic, small, and should therefore be able to
penetrate the blood-brain barrier. Because of these factors, we included umbelliferone among our list of compounds to be tested.

Betulinic acid

BA is another natural product and has been used therapeutically both in Ayurveda and modern medicine. BA is a lupane-type triterpinoid (Figure 1) and a major component in many different plants including *Bacopa monniera*, also known as ‘Bhrami,’ which grows in south Asia26. Extracts of *Bracopa monniera* are used in Ayurvedic medicines for the treatment of CNS disorders and mental function27. They are also thought to improve higher order cognitive processes that are critically dependent on the input of information from our environment such as learning and memory28. In addition, the bark of the white birch, *Betula alba*, which contains BA, has been extensively used by native Americans to treat intestinal disorders. Furthermore, BA has also shown great promise as a potential therapeutic for a variety of cancer types, including neuroectodermal tumors, and is currently in Phase II clinical trials for the treatment of dysplastic nevi with moderate to severe dysplasia. Critically, the hydrophobic nature and small size of BA should enable it to cross the blood-brain barrier, which makes it a compound suitable for the treatment of CNS disorders26.

Therefore, in this report, we investigate whether BA can interact with Aβ42 *in vitro*. We observed that BA binds to Aβ42 and augments its rate of fibril formation in a concentration-dependant manner. In addition, this augmentation appears to occur in such a way as to bypass neurotoxic, soluble intermediates along the fibril aggregation pathway.
Materials and Methods

Materials

Aβ42 was synthesized at the Peptide Synthesis Facility at the Mayo Clinic (Rochester, MN) using routine Fmoc chemistry. MALDI-ToF mass spectrometry revealed > 90% purity of both peptides. SDS, bovine serum albumin, asiatic acid, asiaticoside, umbelliferone, scopoletin, betulinic acid, and thioflavin T were procured from Sigma (St. Louis, MO). All other chemicals were obtained from VWR Inc.

Preparation of Aβ42 monomers

Lyophilized stocks of synthetic Aβ42 were stored at -20 °C, desiccated. Prior to the experiments, any pre-formed aggregates that may have been present were removed via size exclusion chromatography (SEC) as previously reported16. Briefly, 1-1.5 mg of the peptide were dissolved in 0.5 ml of 30 mM NaOH, and allowed to stand at room temperature for 15 min before loading onto a Superdex-75 HR 10/30 size exclusion column (SEC) (GE Life Sciences) attached to an AKTA FPLC system (GE Healthcare, Buckinghamshire). The column was pre-equilibrated in 20 mM Tris-HCl (pH 8.0) at 25 °C and was run at a flow rate of 0.5 mL/min. One minute fractions were collected. Concentrations of the purified fractions were estimated by UV-Vis spectroscopy on a Cary 50 spectrophotometer (Varian Inc) using a molar extinction coefficient (ε) of 1490 cm⁻¹ M⁻¹ (www.expasy.org), corresponding to the single tyrosine residue within Ab42. Peptide integrity after SEC was again confirmed by MALDI-TOF mass spectrometry, which yielded a single peak corresponding to a monoisotopic molecular mass of 4516.31 Da in a good agreement with the calculated mass of 4514.13 Da. A similar purification scheme was also adopted for mutant Aβ42 F19W. Monomeric Aβ42 fractions were
stored at 4 °C and were used within 3 to 4 days of purification in all experiments to avoid the presence of pre-formed aggregates in our reactions.

**Aβ42 oligomer generation**

Aβ42 12-18mers were generated by following the method reported previously. Briefly, 50 µM Aβ42 was incubated with 5 mM lauric acid at 37 °C for 48 h. The sample was then fractionated using a Superdex-75 SEC column and the fractions 17 and 18 were collected for further use.

**Aβ aggregation reactions**

Unless otherwise noted, reactions and measurements were done at room temperature, and samples were stored at 37 °C. Reactions were initiated in 0.5 mL siliconized eppendorf tubes by incubating freshly purified Aβ42 monomer in appropriate conditions in buffer without agitation. Aggregation parameters were obtained by monitoring the reaction with thioflavin T (ThT) fluorescence and fitting fluorescence data points to the sigmoidal curve in eq. 1 using Origin 7.0. In this equation t is time, a and b are fixed parameters, and t_{0.5} is the time to reach half-maximal ThT fluorescence. Lag times were equal to t_{0.5} – 2b for each curve.

**Fluorescence spectroscopy**

ThT fluorescence (F) was monitored in a 1 cm quartz microcuvette with a Cary Eclipse spectrometer (Varian Inc) after 15-fold dilution of Aβ42 samples into 5 mM Tris-
HCl (pH 8.0) containing 10 µM ThT. Continuous measurements of F were taken for 1 min with the excitation and emission wavelengths fixed at 450 and 482 nm respectively and both slits set at 10 nm. The fluorescence blanks were subtracted from the respective data and the average F value was determined.

*Turbidity*

Turbidity was monitored in a 1 cm quartz microcuvette using a Cary 50 UV-Vis spectrophotometer (Agilent Technologies). At the given time points, 70 µL of undiluted sample was placed into the cuvette and absorbance was measured at 400 nm using the 'Simple Read' program provided by the manufacturer in triplicates with 30 s delays.

*Kinetics*

The initial, or zero-hour, kinetics of an Aβ42 aggregation reaction were obtained in a similar fashion to the aggregation reactions already described. For kinetics, however, the reaction was prepared with all components except for the freshly purified Aβ42 monomer. For fluorescence, the fluorescence spectrophotometer was set as above, except with a 15 min collection time. Immediately before measurement, the Aβ42 monomer was mixed with the sample, and 5 µL of sample was combined with 70 µL of ThT in the quartz cuvette. The sample was quickly mixed and inserted into the spectrophotometer for data collection. For UV kinetics, the same sample preparation technique was used, and absorbance measurements were taken on the Cary 50 UV-Vis spectrophotometer using the 'Kinetics' program provided by the manufacturer.
Size exclusion chromatography

Quantitative estimates of aggregation reaction were obtained using a Superdex-75 HR 10/30 size exclusion column (GE Life Sciences) on an AKTA FPLC system. Aliquots of sample from the aggregation reactions were centrifuged and the supernatant (100 µL) was loaded onto the SEC column. The samples were then subjected to fractionation in 20 mM Tris-HCl, pH 8.0 at a constant flow rate of 0.5 mL/min and the elution was monitored at the wavelength of 215 nm.

Polyacrylamide gel electrophoreses (PAGE) and immunoblotting

Samples were dissolved in loading buffer (1x Laemmli buffer) containing 1% SDS, applied without heating to 4-12% NuPage gels (Invitrogen) containing bis-Tris, and resolved in 2-(N-morpholino)ethanesulfonic acid (MES) running buffer with 0.1% SDS. Dye-linked MW markers (Blue Plus2 Prestained Standards, Invitrogen) were run in parallel for calibration. Gels were electroblotted onto 0.45 µm immobilon nitrocellulose membranes (BioTrace™ NT, Life Sciences Inc). Blots were boiled in a microwave oven in PBS for 2 min and were blocked overnight with 1X PBS containing 5% nonfat dry milk and 0.1% tween-20 before probing (1-2 h) with 1:1000-1:2500 dilutions of Ab9 monoclonal antibody, which detects amino acid residues of Aβ (1-16). Blots were then incubated with anti-mouse horseradish peroxide (HRP) conjugate and developed with ECL reagent (Thermo Scientific).
Circular dichroism (CD)

CD spectra were obtained in the far UV region with a Jasco J-815 spectropolarimeter (Jasco Inc, Easton, MD). Aliquots of samples containing Aβ42 (25 µM) were placed in a 0.1 cm path-length quartz cuvette (Hellma) and were monitored in continuous scan mode (260-190 nm). The acquisition parameters were 50 nm/min with 8 s response time, 1 nm bandwidth and 0.1 nm data pitch, and data sets were averaged over three scans. All data were collected in duplicate. Spectra of appropriate blanks were subtracted from the data sets as indicated. The corrected, averaged spectra were smoothed using the ‘means-movement’ algorithm with a convolution width of 25 using the Jasco spectra analysis program.

Fluorescence anisotropy

Binding experiments were carried out by fluorescence anisotropy experiments using an F19W-Aβ42 mutant. The excitation and emission wavelengths were fixed at 280 and 352 nm respectively with a spectral bandwidth of 30 nm (10 nm Ex and 20 nm, Em). The ADL program on spectrometer was used and the G-factor was calculated for each titration using Aβ42 F19W as the fluorophore. Each titration point was measured in quadruplets after a brief equilibration time of 1 min, and the data points were averaged. The data was converted to anisotropy (r) values using the 'Advanced Read' program provided by the manufacturer. The data were fit into the following non-cooperative single site binding equation using Origin 7.0 (Eq 2), where \( r_0 \) and \( r_s \) are anisotropy values in the
absence and saturated levels of the ligand (BA), respectively, while \( L_t \) and \( P_t \) are the respective total ligand and A\( \beta \)42 concentrations.

**Results**

*AA, AS, and UM fail to inhibit A\( \beta \)42 fibrilization*

Using ThT fluorescence as described above, we investigated the effect of asiatic acid, asiaticoside, umbelliferone, and scopoletin on A\( \beta \)42 fibril formation. ThT is an extrinsic dye that is known to show fluorescent properties upon binding to amyloid aggregates\(^{29} \) and hence, it is used as an indicator to monitor A\( \beta \) fibril formation or aggregation.

Figure 1A shows an aggregation profile of each compound incubated at a fourfold molar excess to A\( \beta \)42. Although datasets from replicate incubations could not be averaged due to the slight variation in purity of A\( \beta \)42 monomer, the chosen dataset is typical of all aggregation profiles obtained. All compounds were dissolved in DMSO, except for AS, which was soluble at 300 \( \mu \)M in water. Appropriate controls were included for each solvent. We incubated 25 \( \mu \)M A\( \beta \)42 with 100 \( \mu \)M BA, AA, AS, or UM in 20 mM TRIS, pH 8.0. Appropriate controls were also generated, with the same percentage of DMSO (5\%) included in the DMSO control as was present in the final incubations of BA, AA, and UM. The aqueous control simply contained 25 \( \mu \)M A\( \beta \)42 and 20 mM TRIS at pH 8.0. Betulinic acid (▲) displayed an instantaneous increase in fluorescence, which was sustained throughout the incubation period. Asiatic acid (Δ) and the DMSO control (●) displayed a very similar aggregation profile, reaching a similar maximum level of fluorescence with lag times of approximately 24 h. Earlier incubations had shown umbelliferone to similarly diverge very little from the DMSO control (data
not shown). Asiaticoside (□) displayed no major divergence from the aqueous control (■) in either lag time or maximum fluorescence in this particular incubation, but in other replications it seemed to cause slight inhibition of fibril formation (data not shown).

In order to further investigate the effect of these compounds on aggregation of Aβ42, we incubated them at sixfold excess with E22G-Aβ42 mutant, in which the glutamate residue at position 22 was replaced with glycine. E22G-Aβ42 typically aggregates faster than wild type, and investigating the interaction of compounds with Aβ mutants can help to determine which portions of the Aβ peptide are involved in the interaction. Figure 1B shows that BA (○) again caused an increase in fluorescence with no noticeable lag time, which remained high throughout the incubation. UM (▲) and AA (□) had very similar fluorescence to the DMSO control (●) for the duration of the experiment, and AS (Δ) again displayed very little divergence from the aqueous control (■).

Since AS and BA were the only compounds to show any divergence from their controls, we incubated them at a tenfold molar excess to Aβ42 in an attempt to make their effect more apparent. 25 µM Aβ42 was incubated with 250 µM BA or AS in the same conditions as previously described, with appropriate controls. Figure 1B shows that betulinic acid (○) caused an even greater increase in total fluorescence with no noticeable lag time, compared to the DMSO control (●). On the other hand, asiaticoside (Δ) did not display any inhibitory effect compared to the aqueous control (■) at tenfold excess, suggesting that the slight inhibition seen earlier was an experimental aberration. However, the effect of BA was increased with increasing dosage, a phenomenon which we chose to further investigate and characterize.
BA rapidly augments Aβ42 fibril formation in a concentration dependent manner

We explored the effects of BA on Aβ42 aggregation by ThT fluorescence and turbidity assays. Since BA shows poor solubility in aqueous buffers, we performed our experiments in two different solvents: dimethyl sulphoxide (DMSO) and ethanol (EtOH). As described in a subsequent section, we used EtOH as a solvent to facilitate circular dichroism (CD) measurements, as DMSO is not well tolerated in CD. It was therefore essential to monitor aggregation in both solvents to ensure that the interaction between betulinic acid and Aβ42 was maintained.

We incubated 25 µM of freshly purified, seed-free monomeric Aβ42 with increasing

**Figure 2. ThT Aggregation Profiles.** ThT fluorescence over time for incubations of A) fourfold molar excess of BA (▲), AA (Δ), and AS (□) incubated with Aβ42, along with DMSO control (●) and TRIS control (■); B) sixfold molar excess of BA (○), UM (▲), AA (□), and AS (Δ) incubated with E22G-Aβ42, along with DMSO control (●) and TRIS control (■); and C) tenfold molar excess of BA (○) and AS (Δ), along with DMSO control (●) and TRIS control (■).

**Figure 3. ThT Aggregation Profiles.** ThT fluorescence over time for incubations of A) fourfold molar excess of BA (▲), AA (Δ), and AS (□) incubated with Aβ42, along with DMSO control (●) and TRIS control (■); B) sixfold molar excess of BA (○), UM (▲), AA (□), and AS (Δ) incubated with E22G-Aβ42, along with DMSO control (●) and TRIS control (■); and C) tenfold molar excess of BA (○) and AS (Δ), along with DMSO control (●) and TRIS control (■).
concentrations of BA (from sub-stoichiometric ratio to four-fold excess) at 37 °C. Since the stock solutions (1 mM) of BA were prepared in 100% DMSO or EtOH, incubations of varying Aβ:BA stoichiometry resulted in different final concentrations of DMSO or EtOH in the sample. A ratio of 1:4 Aβ42:BA contained 5%, 1:2 contained 2.5%, 1:1 had 1.25% while 1:0.5 contained 0.625% of DMSO or EtOH. Therefore, appropriate Aβ42 samples in similar solvents but in the absence of BA were used as controls (Figure 3B and 3D). Aliquots of the incubated samples at the given time points were subjected to fluorescence measurement upon addition of ThT buffer as shown in Figure 3A and 3C for DMSO and EtOH, respectively. The data were fit using a sigmoidal equation (Eq. 1 in Materials and Methods) to obtain lag-time information. Incubation in DMSO showed an increase in Aβ42 aggregation rate as observed by both the increase in the fluorescence intensity and the decrease in lag times as compared to the controls. The difference plots shown in Figure 3E show the dose-response effect in which 1:4 ratio (□) had the highest rate of aggregation, followed by 1:2 (▲), 1:1 (○) and 1:0.5 (■). The four-fold excess of BA seemed to show immediate and sharp increase in ThT fluorescence intensity with no noticeable lag-time (□ in Figure 3A and E). Even a sub-stoichiometric ratio of 1:0.5 of Aβ42:BA (■ in Figure 3E) resulted in augmentation of the aggregation rate as indicated by the fluorescence increase after ~50 h of incubation. Similarly, incubations in EtOH also resulted in augmented Aβ42 aggregation rates with lag times similar to those observed with DMSO (Figure 3C). However, control incubations in EtOH but in the absence of BA also resulted in increase in Aβ42 aggregation rates. Nevertheless, the difference plots of the incubations in EtOH shows that there is a net increase in the aggregation rates that is prominent with 1:4 stoichiometry (Figure 3F). It is noteworthy that the incubation at a 1:4 molar ratio showed a rapid increase in ThT fluorescence in
both solvents within the first 24 h (Figures 3E and F). Reproducible results were obtained multiple times for both solvents. However, due to the slight variation in Aβ monomer purity, the lag-times varied, making it difficult to average the data sets. Nevertheless, overall reaction profiles remained identical to the one shown in Figure 2.

Since we observed maximal effect (in ThT measurements) with a fourfold molar excess of BA, we explored only the sample of 25 µM Aβ42 incubated with 100 µM BA in DMSO at 37 °C for the turbidity assay, since its primary purpose was to confirm the validity of ThT measurements. We monitored aggregation by measuring the absorbance at 400 nm in a UV-Vis spectrophotometer as previously described. Aβ42 incubated with BA showed a rapid increase in turbidity within 24 h of incubation and continued to remain high, consistent with the ThT experiments. The control Aβ42 sample in the absence of BA also displayed a similar trend; however, the absorbance intensity was far lower. The difference curve showed a rapid increase during the initial 24 h that remained fairly stable for the remainder of the incubation period. The difference curve was again similar to that for the ThT fluorescence experiment (Figure 3A).

With 1:4 stoichiometric incubations we observed a sharp and apparently instantaneous increase in both fluorescence and absorbance levels (Figures 3A and 4A, respectively), and we wanted to ensure it was not an experimental aberration. Therefore, we monitored the aggregation process immediately upon coincubation of BA and Aβ42. As shown in Figure 4B, both ThT fluorescence and absorbance showed a rapid kinetic process with similar exponential growth rates, suggesting a rapid and considerable increase in aggregation rate induced by BA.
**Figure 3. Dose-dependent augmentation of Aβ42 aggregation by BA.**

Aggregation was measured via ThT fluorescence over time. Incubations comprised of 25 µM Aβ42 in 20 mM Tris, pH 8.0 at 37 °C with increasing amounts of BA dissolved in DMSO; A) 12.5 µM (■), 25 µM (○), 50 µM (▲), 100 µM (□). B) Controls containing DMSO concentrations corresponding to 12.5 µM, 25 µM, 50 µM, and 100 µM BA incubations respectively shown in A: 0.625% (▲), 1.25% (○), 2.5% (□), and 5% (■). C) Incubations comprising buffered 25 µM Aβ42 with increasing amounts of BA dissolved in EtOH; 12.5 µM (■), 25 µM (○), 50 µM (▲), and 100 µM (□). D) Controls containing varying EtOH concentrations; 0.625% (■), 1.25% (○), 2.5% (▲), and 5% (□). E) Difference plot of BA dissolved in DMSO (A) and DMSO controls (B). The control fluorescence at each time point was subtracted from the fluorescence of the BA samples to generate the plot, which shows the molar stoichiometric incubations, 1:0.5 (■), 1:1 (○), 1:2 (▲), and 1:4 (□). F) Similar difference plot of BA dissolved in EtOH (C) and EtOH controls (D), which shows the molar stoichiometric incubations, 1:0.5 (■), 1:1 (○), 1:2 (▲), and 1:4 (□). The Aβ:BA stoichiometry is indicated by dotted arrows in E and F.
Sedimentation and SEC assays also indicate rapid Aβ fibrilization in the presence of BA.

In order to quantify the proportion of monomeric Aβ42 being converted to insoluble fibrils, we monitored the aggregation process by using sedimentation and size exclusion chromatography (SEC). We monitored the depletion of monomers when Aβ42 was incubated with BA in comparison to a control in the absence of BA using a
Superdex-75 SEC column. Since we observed the maximum difference between experimental and control samples after 24 h of incubation with a fourfold molar excess of BA (Figure 3A and 4A), we decided to fractionate a sample containing 25 µM Aβ42 and 100 µM BA, as well as a 25 µM Aβ control, after 24 h incubation at 37 °C. First, we centrifuged each sample at 19,000 g for 15 minutes in order to sediment any pre-formed insoluble fibrils that may have interfered with the SEC column. The supernatant was then loaded on to the column for fractionation. The Aβ42 control incubation in the absence of BA showed a distribution containing mainly the monomeric peak, which eluted in fractions, 24 and 25 along with a minor amount of aggregated material eluting near the void volume (V₀) of the column (Figure 4C; dotted line). The Aβ42 sample in the presence of BA showed a similar fractionation profile (Figure 4C; solid line); however, the amount of monomer was far less than that of the control sample. This suggests that the presence of BA promotes rapid fibril formation, leading to a concomitantly decrease in the amount of monomers. Furthermore, it is interesting to note that the sample with BA also contained some aggregates that eluted near the void volume (Figure 4C; inset). However, the amount of the aggregated peak was less than that observed for the control sample. Since these aggregates were non-fibrillar, soluble intermediates (as the fibrils had been spun out prior to fractionation), this observation suggests that BA promotes insoluble fibril formation at the expense of soluble aggregates. Finally, in order to ensure that the aggregates formed in the presence of BA are indeed fibrils, we performed a sedimentation assay. After 24 hours of incubating 25 µM Aβ42 with BA in fourfold excess, we measured ThT fluorescence as previously described. We then spun the sample at 19,000 g for 15 minutes and measured the ThT fluorescence of the supernatant. As shown in Figure 4D (grey bars), only ~30 % of fluorescence was observed after
sedimentation, suggesting a large amount fibril formation within 24 h of incubation. Furthermore, mass spectrometry analysis of the supernatant and pellet from the co-incubated sample after multiple spins, rinsing the pellet each time, revealed that all BA was associated with the fibrils and none was observed in the supernatant (data not shown), suggesting that BA is incorporated or tightly complexed with the fibrillar structure. Collectively, these data suggest that BA was able to rapidly promote the formation of insoluble Aβ42 fibrils from monomeric species and bypass soluble oligomeric intermediates in doing so.

*Oligomers are absent in co-incubations of Aβ42 and BA*

We also subjected the samples incubated in Figures 3A and B to electrophoresis and immunoblotting to see whether the results complemented the experiments described above. Shown in Figure 5 are immunoblots of samples of Aβ42 with a fourfold excess of BA prepared in the same fashion as those in Figure 3A, along with appropriate controls. Clearly, the control sample in the absence of BA showed no high molecular weight bands for 24 h.

**Figure 5.** Aβ42 aggregation in the presence of BA monitored by immunoblots. Samples containing 25 μM Aβ42 were incubated alone (control) or with 100 μM BA (+BA) at 37 °C. The aliquots of the sample was taken at the indicated time points and were run on a SDS-PAGE gel followed by western blotting and immunodetection. The lanes T & S represent total and supernatant (after spinning the sample at 19000g for 20 min to remove fibrils) respectively, after 0, 24 & 48 h of incubation.
After 48 h, aggregate bands of ~100 kDa were apparent, along with some high molecular weight bands that failed to enter the gel consistent with fibrils (F) (Figure 5A: 48 h). In contrast, samples with BA showed a fibril band (F) within 24 h of incubation. More importantly, the supernatant after centrifuging the sample at 19000g for 15 minutes failed to show the high molecular band (Figure 5B; 24 h, S), confirming that these bands correspond to fibrils. A similar pattern was observed after 48 h of incubation (Figure 5B; 48 h). Although the control sample showed similar bands at 48 h, they were also present in the supernatant, suggesting the bands may correspond to non-fibrillar, ‘non-pelletable’ forms of aggregates. These results confirm that BA is able to promote insoluble fibril formation from Aβ42 monomer within 24 hours and also suggest that this occurs in a manner that bypasses the formation of soluble, pre-fibrillar aggregates.
BA induces rapid changes in Aβ42 secondary structure.

Figure 6. Secondary structure changes in Aβ42 upon incubation with BA. Co-incubation reactions containing four-fold molar excess of BA in EtOH similar to those shown in Figure 2C were monitored using far-UV CD (solid lines) along with control in the absence of BA (dashed lines) at the indicated time points (A-D). E) The difference plot obtained by subtracting the molar ellipticity values at 216 nm of the control sample from the sample containing BA (■), which was overlayed with the difference plot shown in Figure 2F for 1:4 stoichiometry (○).

The secondary structure changes during the incubation of Aβ42 with BA were monitored by far-UV CD spectroscopy. Since DMSO solvent is not compatible with CD measurements, Aβ42 was incubated in a fourfold excess of BA in 5% EtOH along with an appropriate control as in Figure 3C and 3D. Both the control sample and the one co-incubated with BA displayed a random coil conformation immediately (10 min) after incubation (Figure 6A). However, the molar ellipticity at 216 nm was slightly more
negative for the sample with BA, suggesting a conformational change toward β-sheet. After 24 h of incubation, the sample containing BA clearly displayed a spectrum with negative minimum at 216 nm and positive maximum at ~198 nm, indicating a β-sheet conformation characteristic of Aβ fibrils (Figure 6B). By contrast, the control sample displayed predominantly a random coil structure (Figure 6B). After 48 h, both the control as well as the sample containing BA showed β-sheet conformation and remained in the same conformation for more than 120 h (Figure 6C and 6D). A comparison of the difference spectra obtained from ThT and CD experiments indicated identical changes (Figure 6E). It is clear that the maximal difference of BA compared to controls was observed during the initial 24 h of incubation, which complements the results obtained from ThT, turbidity, SEC, sedimentation assays, and immunoblots.

**BA binds to monomeric Aβ42 with sub-micromolar binding affinity.**

Finally, we wanted to explore the binding interaction between Aβ42 and BA. In order to do so, we used an Aβ42 F19W mutant peptide in which the phenylalanine at the 19th position was substituted with a tryptophan residue to facilitate fluorescence anisotropy measurements. Although the wild-type Aβ contains a tyrosine (Tyr) residue at the 10th position, Tyr is not a good fluorophore and the emission intensities were prohibitively low for anisotropy experiments. Aβ40 F19W mutant has been previously observed to exhibit no significant difference in aggregation and fibril formation compared to wild type Aβ4031. To ensure that there was also no significant difference between wild-type Aβ42 and the mutant, we performed ThT experiments both in the presence and in the absence of BA (data not shown). These experiments did not show significant divergence from aggregation profile of wild-type Aβ42. Upon titrating BA to
a freshly purified monomeric Aβ42 F19W sample, we observed a constant increase in tryptophan anisotropy ($r$) reflecting binding interaction between the two species (Figure 7; ●). Fitting the data using the non-interacting one-site binding equation (Equation 2) yielded an apparent dissociation constant ($K_D^{app} = 11.02 \pm 2.01$ µM).

Since BA induces rapid aggregation, especially at high molar ratios, the FA experiments may not reflect the binding interactions between BA and monomeric Aβ exclusively. For this reason, we refer to the binding affinity as 'apparent,' $K_D^{app}$. A dipeptide, glycylglycine (GG) was used as a negative control and did not show any appreciable binding isotherm (Figure 7; ○).

**Figure 7.** Binding affinity between Aβ42 and BA measured by fluorescence anisotropy. The specific mutant, F19W Aβ42 was used as a probe to measure tryptophan anisotropy ($r$). Aliquots of mixtures containing 5 µM Aβ42 and 50 µM BA in 2.5 % DMSO was titrated on a solution containing 5 µM Aβ42 in a similar solvent (●). The anisotropy was measured in quadruplets for each titration points that were averaged. As a negative control similar experiment was performed using glycylglycine instead of BA (○). Three independent data sets were averaged and fit with a model for a single site binding (Eq 2).
**Discussion**

The design of therapeutics for any disease is a process that faces many challenges. Synthetic, rationally designed drugs, while having excellent potential for specificity, require the development of an efficient synthetic pathway and extensive testing for toxicity. As the world saw with Thalidomide in the 1970's, even a simple change in stereochemistry can lead to vastly altered biological effects. Natural products offer an attractive alternative to synthetic drugs. They are generally produced in abundant quantities in plants or herbs, the efficacy of their synthesis has been streamlined by millions of years of evolution, and they are often already components of the human diet. In addition, many of these products are already in use in ancient forms of traditional medicine, such as the Ayurvedic system of India. It is entirely likely thorough screening of the natural products used in traditional herbal remedies and concoctions will yield a plethora of active compounds and combinations of compounds that can provide significant benefits to human health.

The compounds tested here are all components of such concoctions, and it is important to note that even if a compound does not directly alter the aggregation of Aβ, it still has the potential to be beneficial in the treatment of AD. For asiatic acid and asiatoside, this is almost certainly the case. Although our investigations yielded no direct interaction between the Aβ42 peptide and either molecule, they have both been shown by previous researchers to be beneficial in this regard\textsuperscript{19-24}. Umbelliferone has not been extensively researched in connection to AD, and again, although we showed no direct interaction between it and Aβ42 \textit{in vitro} aggregation, they may still provide some \textit{in vivo} benefit that our assays did not detect. Betulinic acid proved not to be an aggregation inhibitor, which is the type of compound we initially sought, but it may still mitigate the
AD pathology in some way, especially considering its ability to promote the formation of fibrils at the expense of neurotoxic oligomers, discussed in greater detail below.

The development of Aβ aggregation inhibitors in particular involves several challenges; a) the difficulty in controlling the stage of inhibition during the aggregation process, and b) the possible increase in the soluble oligomer concentrations upon inhibition of fibril formation may be detrimental, as smaller soluble oligomers are known to more toxic than fibrils. Therefore, an ideal way of developing therapeutically viable aggregation inhibitors would be to trap Aβ at the monomeric level, since monomers are not toxic. However, it is difficult to design molecules against intrinsically disordered, monomeric Aβ due to its high conformational flexibility and lack of structurally well-defined recognition motifs. Considering such difficulties, it is not surprising that few aggregation inhibitors have successfully made it though the clinical trials.

In this context, it is perhaps worthwhile to consider designing molecules that can prevent the formation of neurotoxic oligomers by circumventing these pathogenic species. The results reported here suggest BA is precisely able to perform such a task and showcase the potential use of BA as a therapeutic agent against AD. The mechanism of augmentation of aggregation by BA is not entirely a new observation as previously, compounds such as methylene blue and ellagic acid have also been reported to promote rapid Aβ42 fibril formation and inhibit neurotoxicity^{30,32}. 
However, the rapid fibrillation induced by BA as reported here, which comes at the expense of toxic soluble oligomers, seems to be exclusive to the fibril formation ‘on-pathway’. As it is increasingly becoming evident that many neurotoxic oligomers can be formed outside the obligatory fibril formation pathway, we explored whether BA is able to circumvent such oligomer formation also. BA failed to induce the formation of fibrils and concomitantly inhibit the formation of 12-18mer oligomers (Figure 8; lanes 1 and 2), which were reported to be formed along an alternate pathway of aggregation called ‘off-pathway’\(^\text{16}\). In addition, BA failed to convert isolated 12-18mers to fibrils rapidly as observed with monomers (Figure 8), suggesting that BA is unable to interact with oligomers that are not formed along the fibril formation ‘on-pathway’. These suggest that; a) BA is extremely potent in promoting rapid fibril formation along the ‘on-pathway’, and b) BA is incapable of interacting with aggregates along alternate pathways of aggregation.

**Figure 8.** Effect of BA on ‘off-pathway’ oligomers. Lanes 1 & 2 show 25 µM Aβ42 containing 5 % DMSO incubated with 5mM lauric acid alone and in the presence of 100 µM BA respectively. In parallel, the SEC isolated oligomers were also incubated alone and with 100 µM BA at 37 °C. The aliquots of the sample was taken at the indicated time points and were electrophoresed and immunoblotted. The lanes T & S represent total and supernatant (after spinning the sample at 19000g for 20 min to remove fibrils) respectively, after 0 & 24 h. The double arrows indicate 12-18mer oligomers of Aβ42.
Pharmacologically, the properties of BA are well known, and the compound is being administered for a variety of pathologies. Historically, extracts of *Bracopa monniera* have been used in Ayurvedic medicines for the treatment of CNS disorders and impaired mental function\(^ {27,33}\). They are also thought to improve higher order cognitive processes that are critically dependent on the input of information from our environment such as learning and memory\(^ {33}\). In addition, white birch bark, *Betula alba*, which contains BA, has been extensively used by native Americans to treat intestinal disorders. BA is also widely used in modern medicine\(^ {34-39,43}\). BA has shown great promise as a potential therapeutic for a variety of cancer types, and, furthermore, BA is also known to inhibit HIV viral replication\(^ {36,40}\). Due to the distinct pharmacological advantages of BA as a therapeutic agent along with its unique property of promoting Aβ fibril formation and especially bypassing toxic oligomers along the ‘on-pathway’ fibril formation as reported here, BA is an excellent therapeutic candidate for AD. Therefore, understanding the effects of BA in *in vivo* systems such as cell culture and animal models is imperative for drug development. Our future experiments are focused on addressing these aspects and will be published later.
References


